专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07309695B2 Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA 有权
标题翻译：用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物
公开(公告)号：US07309695B2
公开(公告)日：2007-12-18
申请号：US10703783
申请日：2003-11-06
申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
发明人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
IPC分类号： C07H21/04 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译：本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。

2. 发明授权

US07820160B2 Midkine inhibitory compositions for the treatment of angiostenosis 有权
标题翻译：用于治疗血管狭窄的中期抑制组合物
公开(公告)号：US07820160B2
公开(公告)日：2010-10-26
申请号：US11936438
申请日：2007-11-07
申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
发明人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译：本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。

3. 发明申请

US20080107659A1 Pharmaceutical Compositions for the Prevention and Treatment of Atherosclerosis and Restenosis After PTCA 有权
标题翻译：用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物
公开(公告)号：US20080107659A1
公开(公告)日：2008-05-08
申请号：US11936438
申请日：2007-11-07
申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
发明人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译：本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。

4. 发明授权

US08288343B2 Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation 有权
标题翻译：通过中期因子激活内皮一氧化氮合酶，并用于实现血管舒张
公开(公告)号：US08288343B2
公开(公告)日：2012-10-16
申请号：US12593277
申请日：2008-03-28
申请人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
发明人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
IPC分类号： A61K38/00 , A61K38/22 , A61K38/16
CPC分类号： C07K14/475 , A61K38/00
摘要： The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.
摘要翻译：目的是找到一氧化氮合酶激活剂，给予激活剂的方法和待施用的活化剂的量。公开了包含中期因子家族蛋白或中期因子衍生物作为活性成分的一氧化氮合酶激活剂。具体公开了旨在通过血液，冠状动脉或静脉施用的一氧化氮合酶激活剂，其包含中期因子家族蛋白或中期因子衍生物作为活性成分。

5. 发明申请

US20100197577A1 NITRIC OXIDE SYNTHASE ACTIVATOR 有权
标题翻译：硝酸氧化酶活化剂
公开(公告)号：US20100197577A1
公开(公告)日：2010-08-05
申请号：US12593277
申请日：2008-03-28
申请人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
发明人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
IPC分类号： A61K38/16 , C12N9/00
CPC分类号： C07K14/475 , A61K38/00
摘要： The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.
摘要翻译：目的是找到一氧化氮合酶激活剂，给予激活剂的方法和待施用的活化剂的量。公开了包含中期因子家族蛋白或中期因子衍生物作为活性成分的一氧化氮合酶激活剂。具体公开了旨在通过血液，冠状动脉或静脉施用的一氧化氮合酶激活剂，其包含中期因子家族蛋白或中期因子衍生物作为活性成分。

6. 发明授权

US09023799B2 Method to reduce loss of cardiac function following ischemia/reperfusion 有权
标题翻译：缺血/再灌注后减少心脏功能损失的方法
公开(公告)号：US09023799B2
公开(公告)日：2015-05-05
申请号：US11720983
申请日：2005-12-06
申请人： Mitsuru Horiba , Itsuo Kodama , Takashi Muramatsu , Kenji Kadomatsu
发明人： Mitsuru Horiba , Itsuo Kodama , Takashi Muramatsu , Kenji Kadomatsu
IPC分类号： A61K38/00 , A61K38/16 , A61K38/18
CPC分类号： A61K38/18
摘要： A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.
摘要翻译：描述了通过向需要这种治疗的受试者施用Midkine来治疗缺血或再灌注后心脏损伤的慢性期的方法。

7. 发明申请

US20100056437A1 Compositions for Treating or Preventing Myocardial Damage or Heart Failure 有权
标题翻译：治疗或预防心肌损伤或心力衰竭的组合物
公开(公告)号：US20100056437A1
公开(公告)日：2010-03-04
申请号：US11720983
申请日：2005-12-06
申请人： Mitsuru Horiba , Itsuo Kodama , Takashi Muramatsu , Kenji Kadomatsu
发明人： Mitsuru Horiba , Itsuo Kodama , Takashi Muramatsu , Kenji Kadomatsu
IPC分类号： A61K38/16
CPC分类号： A61K38/18
摘要： The present inventors compared myocardial damages after ischemia/reperfusion in wild-type mice and Midkine (MK)-deficient mice to confirm the effects and functions of MK. MK administration was found to significantly prevent cardiomyocyte apoptosis in both cultured cardiomyocytes (in vitro) and mouse models (in vivo).
摘要翻译：本发明人比较野生型小鼠和Midkine（MK）缺陷小鼠缺血/再灌注后的心肌损伤，以证实MK的作用和功能。发现MK给药在培养的心肌细胞（体外）和小鼠模型（体内）中显着预防心肌细胞凋亡。

8. 发明申请

US20100105613A1 THERAPEUTIC AGENT FOR OCCLUSIVE PERIPHERAL VASCULAR DISEASE, AND USE THEREOF 审中-公开
标题翻译：用于治疗外周血管疾病的治疗药物及其用途
公开(公告)号：US20100105613A1
公开(公告)日：2010-04-29
申请号：US12446446
申请日：2007-10-19
申请人： Mitsuru Horiba , Itsuo Kodama , Kenji Kadomatsu
发明人： Mitsuru Horiba , Itsuo Kodama , Kenji Kadomatsu
IPC分类号： A61K38/16 , A61K31/7052 , A61P9/00
CPC分类号： A61K48/005 , A61K38/00 , C07K14/475
摘要： A study was made on the therapeutic effect of midkine on an occlusive peripheral vascular disease, and it was found that midkine has an activity of promoting neovascularization and that a blood vessel can be proliferated and the blood flow in the upper and lower limbs can be improved (in other words, the condition of an ischemic disease in the upper and lower limbs can be ameliorated) by introducing midkine into a site affected by the occlusive peripheral vascular disease.
摘要翻译：对中期因子对闭塞性外周血管疾病的治疗作用进行了研究，发现中期因子具有促进新生血管形成的活性，并且血管可以增殖，并且能够改善上肢和下肢的血流量（换句话说，上肢和下肢的缺血性疾病的病症可以改善），通过将中期因子引入受封闭性外周血管疾病影响的部位。

9. 发明申请

US20050234409A1 Catheter 审中-公开
标题翻译：导管
公开(公告)号：US20050234409A1
公开(公告)日：2005-10-20
申请号：US10518822
申请日：2003-06-20
申请人： Mitsuru Horiba , Nobumasa Tsutsui , Yasuhiro Tsutsui
发明人： Mitsuru Horiba , Nobumasa Tsutsui , Yasuhiro Tsutsui
IPC分类号： A61B17/00 , A61B17/28 , A61B17/34 , A61M25/00 , A61M31/00
CPC分类号： A61B17/29 , A61B17/3478 , A61B2017/00247 , A61B2017/00292 , A61B2017/00336 , A61B2017/00349 , A61B2017/00353 , A61B2017/2845 , A61B2017/2905 , A61B2017/2933 , A61B2017/2946 , A61B2017/3488 , A61B2018/00392 , A61M2025/0089
摘要： A catheter which allows injection into a target region without imposing large burden on a medical patient can be provided. A catheter (1) is used by being inserted from outside of a body into a blood vessel and a distal end thereof being reached inside of a heart, that is a target region, while a proximate end thereof remaining outside of the body. The catheter (1) is configured in a way so that an injection mechanism (5) conducts injection into myocardium from inside of a heart while a forceps mechanism (3) holds myocardium inside of the heart. In the forceps mechanism (3), a grasping portion (13) provided at the distal end of the catheter (1) opens and closes in conjunction with manipulation at a first handling portion (11) provided at the proximate end of the catheter (1). In the injection mechanism (5), an injection needle (43) provided at the distal end of the catheter (1) is protruded from the distal end of the catheter (1) in conjunction with manipulation at a second handling portion (41) provided at the proximate end of the catheter (1).
摘要翻译：可以提供允许注射到目标区域而不对医疗患者施加巨大负担的导管。导管（1）通过从身体的外部插入到血管中并且其远端到达心脏的内部即目标区域，而其近端保持在身体外部。导管（1）以这样的方式配置，使得注射机构（5）在心脏内部从心脏内部进入心肌内注入，而钳子机构（3）将心肌保持在心脏内部。在钳子机构（3）中，设置在导管（1）的远端处的抓握部分（13）与设置在导管（1）的近端处的第一处理部分（11）一起打开和关闭）。在注射机构（5）中，设置在导管（1）的远端处的注射针（43）与导管（1）的远端一起在第二处理部分（41）处的操作中突出，所述第二处理部分在导管（1）的近端处。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式